234 related articles for article (PubMed ID: 20713623)
1. New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.
Goodman AL; Epp C; Moss D; Holder AA; Wilson JM; Gao GP; Long CA; Remarque EJ; Thomas AW; Ammendola V; Colloca S; Dicks MD; Biswas S; Seibel D; van Duivenvoorde LM; Gilbert SC; Hill AV; Draper SJ
Infect Immun; 2010 Nov; 78(11):4601-12. PubMed ID: 20713623
[TBL] [Abstract][Full Text] [Related]
2. Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.
Biswas S; Spencer AJ; Forbes EK; Gilbert SC; Holder AA; Hill AV; Draper SJ
J Immunol; 2012 May; 188(10):5041-53. PubMed ID: 22504652
[TBL] [Abstract][Full Text] [Related]
3. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
[TBL] [Abstract][Full Text] [Related]
4. Prime-boost vectored malaria vaccines: progress and prospects.
Hill AV; Reyes-Sandoval A; O'Hara G; Ewer K; Lawrie A; Goodman A; Nicosia A; Folgori A; Colloca S; Cortese R; Gilbert SC; Draper SJ
Hum Vaccin; 2010 Jan; 6(1):78-83. PubMed ID: 20061802
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.
Nurul AA; Norazmi MN
Parasitol Res; 2011 Apr; 108(4):887-97. PubMed ID: 21057812
[TBL] [Abstract][Full Text] [Related]
6. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
Ogwang C; Afolabi M; Kimani D; Jagne YJ; Sheehy SH; Bliss CM; Duncan CJ; Collins KA; Garcia Knight MA; Kimani E; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Spencer AJ; Soipei P; Mueller J; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Gantlett K; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Urban BC; Flanagan KL; Ewer KJ; Chilengi R; Hill AV; Bojang K
PLoS One; 2013; 8(3):e57726. PubMed ID: 23526949
[TBL] [Abstract][Full Text] [Related]
8. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.
Elias SC; Collins KA; Halstead FD; Choudhary P; Bliss CM; Ewer KJ; Sheehy SH; Duncan CJ; Biswas S; Hill AV; Draper SJ
J Immunol; 2013 Feb; 190(3):1135-47. PubMed ID: 23293353
[TBL] [Abstract][Full Text] [Related]
9. Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
Elias SC; Choudhary P; de Cassan SC; Biswas S; Collins KA; Halstead FD; Bliss CM; Ewer KJ; Hodgson SH; Duncan CJ; Hill AV; Draper SJ
Immunology; 2014 Apr; 141(4):628-44. PubMed ID: 24303947
[TBL] [Abstract][Full Text] [Related]
10. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.
Biswas S; Dicks MD; Long CA; Remarque EJ; Siani L; Colloca S; Cottingham MG; Holder AA; Gilbert SC; Hill AV; Draper SJ
PLoS One; 2011; 6(6):e20977. PubMed ID: 21698193
[TBL] [Abstract][Full Text] [Related]
11. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
Draper SJ; Biswas S; Spencer AJ; Remarque EJ; Capone S; Naddeo M; Dicks MD; Faber BW; de Cassan SC; Folgori A; Nicosia A; Gilbert SC; Hill AV
J Immunol; 2010 Dec; 185(12):7583-95. PubMed ID: 21098232
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
13. Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.
Forbes EK; Biswas S; Collins KA; Gilbert SC; Hill AV; Draper SJ
J Immunol; 2011 Oct; 187(7):3738-50. PubMed ID: 21876036
[TBL] [Abstract][Full Text] [Related]
14. Liver-Directed AAV8 Booster Vaccine Expressing
Shahnaij M; Iyori M; Mizukami H; Kajino M; Yamagoshi I; Syafira I; Yusuf Y; Fujiwara K; Yamamoto DS; Kato H; Ohno N; Yoshida S
Front Immunol; 2021; 12():612910. PubMed ID: 34248928
[TBL] [Abstract][Full Text] [Related]
15. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
Sheehy SH; Duncan CJ; Elias SC; Collins KA; Ewer KJ; Spencer AJ; Williams AR; Halstead FD; Moretz SE; Miura K; Epp C; Dicks MD; Poulton ID; Lawrie AM; Berrie E; Moyle S; Long CA; Colloca S; Cortese R; Gilbert SC; Nicosia A; Hill AV; Draper SJ
Mol Ther; 2011 Dec; 19(12):2269-76. PubMed ID: 21862998
[TBL] [Abstract][Full Text] [Related]
16. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
Bruder JT; Stefaniak ME; Patterson NB; Chen P; Konovalova S; Limbach K; Campo JJ; Ettyreddy D; Li S; Dubovsky F; Richie TL; King CR; Long CA; Doolan DL
Vaccine; 2010 Apr; 28(18):3201-10. PubMed ID: 20188680
[TBL] [Abstract][Full Text] [Related]
17. Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen.
Andersson AC; Resende M; Salanti A; Nielsen MA; Holst PJ
Vaccine; 2017 Feb; 35(8):1140-1147. PubMed ID: 28131394
[TBL] [Abstract][Full Text] [Related]
18. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
[TBL] [Abstract][Full Text] [Related]
19. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
[TBL] [Abstract][Full Text] [Related]
20. Effect of GPI anchor moiety on the immunogenicity of DNA plasmids encoding the 19-kDa C-terminal portion of Plasmodium falciparum MSP-1.
Li G; Basagoudanavar SH; Gowda DC
Parasite Immunol; 2008; 30(6-7):315-22. PubMed ID: 18422871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
